1. The latest crowdfunder to support David Tuller's work has opened. To donate click here.
    Dismiss Notice
  2. Guest, the two part 'News in Brief' for the week beginning 11th October 2021 is here.
    Dismiss Notice
  3. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and ME/CFS:Striking Back on Treatments 2019 Oltra et al

Discussion in 'BioMedical ME/CFS Research' started by Sly Saint, Mar 18, 2019.

  1. Sly Saint

    Sly Saint Senior Member (Voting Rights)

    Messages:
    6,840
    Location:
    UK
    Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking Back on Treatments

    Eloy Almenar-Pérez 1, Teresa Sánchez-Fito 1, Tamara Ovejero 2, Lubov Nathanson 3,4 and Elisa Oltra 2,5,*
    1
    Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, 46001 Valencia, Spain
    2
    School of Medicine, Universidad Católica de Valencia San Vicente Mártir, 46001 Valencia, Spain
    3
    Kiran C Patel College of Osteopathic Medicine, Nova Southeastern University, Ft Lauderdale, FL 33314, USA
    4
    Institute for Neuro Immune Medicine, Nova Southeastern University, Ft Lauderdale, FL 33314, USA
    5
    Unidad Mixta CIPF-UCV, Centro de Investigación Príncipe Felipe, 46012 Valencia, Spain

    https://www.mdpi.com/1999-4923/11/3/126
     

Share This Page